

Data Patterns India (DATAPATT)

Defence | 3QFY25 Result Update

CMP: Rs2,027 | Target Price (TP): Rs2,423 | Upside: 19.5% February 6, 2025

BUY

Performance broadly in line with expectations

Key Points

- Key indicators Revenue, EBITDA, and PAT fell by 16.1%, 10%, and 12.4%, respectively, to Rs. 1.2bn, Rs. 540mn, and Rs. 447 mn (NBIE estimates: Rs. 1.6bn, Rs. 553mn, and Rs. 455 mn), due to a customer's deferral of delivery schedule; nonetheless, overall execution momentum remains high. The export market accounted for a significant share of revenue and order inflow in the 3QFY25. The company is concentrating on developing and designing intellectual property-based products in India, as well as increasing efforts to introduce and increase the presence of indigenous products in international markets. The order book is robust at Rs.11.84 billion, including negotiated orders, with growth in both development and production contracts as of date. The export order book is at Rs. 1.06 billion as of December 31, 2024. Over the next 18 months, the company expects to get fresh orders worth Rs. 20 to 30 bn.
- ➤ Company guidance and Outlook: The management expects a significant increase in the 4QFY25 and is optimistic about reaching a 25% revenue growth for FY25, while sustaining robust EBITDA margins between 35% and 40%.
- Estimates and Rating: Revenue growth, gross margin, and EBITDA margin are projected for FY25, FY26, and FY27 at 10.2%, 23.9%, and 21.5%, respectively; 68.5%, 67.3%, and 68.3%; and 39%, 38.9%, and 37.5%, respectively, consistent with management guidance. The company's trajectory is shifting towards export markets, which is likely to support consistent growth and diversification within its overall order pipeline. Additionally, there is a strategic allocation of funds to enhance product development, with a significant portion directed to expanding R&D capabilities. This approach will help develop next-generation products in accordance with evolving industry requirements and technological advancements. The company has advanced within the value chain by developing integrated systems that utilise reusable building blocks. It is leveraging its capabilities to penetrate international markets including Europe and East Asia while strategically positioning itself against leading OEMs. Moreover, effective implementation to enhance operating leverage, maintaining a net-debt free balance sheet, and ongoing product development to broaden the total addressable market have led to an improved revenue composition. The stock is trading at a 1-year forward P/E of 43.4x, which is below its 2-year average of 62.7x. We maintain a BUY rating on DATAPATT and value it at 62x Dec'26E EPS, in line with its 2-year average P/E, supported by a healthy order book and implying an upside of 19.5%.

Est Change	Downward
TP Change	Downward
Rating Change	No Change

Company Data and Valuation Summary

Reuters:	DATP.BO
Bloomberg:	DATAPATT IN
Mkt Cap (Rsbn/US\$bn):	113.5 / 1.3
52 Wk H / L (Rs):	3,655 / 1,751
ADTV-3M (mn) (Rs/US\$):	493.3 / 5.8
Stock performance (%) 1M/6M/1yr:	(18.4) / (31.6) / 7.3
Nifty 50 performance (%) 1M/6M/1yr:	0.3 / (1.9) / 8.1

Shareholding	1QFY25	2QFY25	3QFY25
Promoters	42.4	42.4	42.4
DIIs	8.5	8.7	8.8
FIIs	15.0	14.4	14.1
Others	34.1	34.5	34.7
Pro pledge	0.0	0.0	0.0

Financial and Valuation Summary

Particulars (Rsmn)	FY24	FY25E	FY26E	FY27E
Net Sales	5,198	5,728	7,099	8,623
Growth YoY%	14.6	10.2	23.9	21.5
Gross margin %	68.2	68.5	67.3	68.3
EBITDA	2,216	2,237	2,764	3,237
EBITDA margin %	42.6	39.0	38.9	37.5
Adj PAT	1,817	1,842	2,246	2,543
Growth YoY%	46.5	1.4	21.9	13.2
Adj EPS	32.4	32.9	40.1	45.4
RoCE	12.3	11.2	12.5	12.9
RoE	14.6	13.2	14.4	14.5
RoIC	19.8	16.5	19.9	21.2
P/E	60.7	59.9	49.1	43.4
EV/EBITDA	48.0	47.1	37.5	31.9
P/BV	8.3	7.5	6.7	6.0

Source: Bloomberg, Company, Nirmal Bang Institutional Equities Research

Key Links: 3QFY25 Result

Please refer to the disclaimer towards the end of the document.



3QFY25 performance update: Revenue declined by 16% YoY, primarily due to the deferred delivery of a completed product and delayed receipt of the order. Production/Development/Service contributed 59%/37%/4% of the revenue, respectively. Of which, Radar and Automated Test Equipment contributed 62% and 18% of the revenue, respectively. EBITDA also saw a decline of ~10% YoY due to the deferred payment. However, EBITDA margins improved by 313bps YoY, rising from 43.0% to 46.2%, driven by a more favourable product mix. The APAT decreased by 12.4% YoY, from Rs 510mn to Rs 447mn, due to higher interest expenses. Despite these challenges, the company maintains a net-debt-free balance sheet, with cash, cash equivalents, and investments of Rs5.7bn. Inventory days were higher due to two large contracts for Radars undertaken by the company. One of these contracts will be delivered by March 2025 and the other will be delivered by Q1/Q2FY26. The management is confident about reaching the full year guidance of 25% revenue growth in FY25 while maintaining EBITDA Margins of 35-40%.

Order book position: The company maintains an order book of Rs 11.8bn, including Rs 890mn in negotiated orders, with a 2.5x growth in order inflow to Rs 2.4bn in 3QFY25 compared to 3QFY24, bringing the total for 9MFY25 to Rs 3.2bn. This growth has been driven by both development and production contracts, particularly in the export market, which remains a key focus for expansion. International order books currently stand at Rs 1bn, accounting for 9% of the total, with expectations of an additional Rs 20-30bn in the coming months. In Q3, the company secured a production order for Electronic Warfare Systems worth Rs 800mn, a Radar production order worth Rs 530mn, and an Avionics export order also worth Rs 530mn.

Exhibit 1: 3QFY25 consolidated performance


Particulars (Rsmn)	1Q24	2Q24	3Q24	4Q24	1Q25	2Q25	3Q25	4Q25E	FY24	FY25E
Net Sales	897	1,083	1,395	1,823	1,041	910	1,170	2,607	5,198	5,728
YoY Change (%)	31.1	22.8	24.8	(1.5)	16.0	(16.0)	(16.1)	43.0	14.6	10.2
Expenditure										
Raw Material Consumed	402	484	415	507	415	496	785	1,014	1,808	2,710
Changes in Inventory	(80)	(148)	36	5	(127)	(277)	(555)	54	(157)	(904)
Employee Costs	230	257	262	265	288	266	292	384	990	1,230
Other Expenses	66	83	82	116	93	82	108	173	341	456
Total Expenditure	618	676	795	893	669	567	630	1,625	2,982	3,492
EBITDA	279	408	600	930	372	343	540	981	2,216	2,237
YoY Change (%)	31.0	35.0	27.6	26.8	33.4	(15.8)	(10.0)	5.5	28.9	0.9
Margin (%)	31.1	37.6	43.0	51.0	35.7	37.7	46.2	37.7	42.6	39.0
Depreciation	29	31	33	70	31	35	35	89	161	189
Interest	17	23	23	30	30	28	32	32	93	121
Other income	116	108	113	123	123	120	114	120	460	477
Extraordinary Items	-	-	-	-	-	-	-	-	-	-
PBT (bei)	349	463	657	953	435	400	588	981	2,422	2,403
PBT	349	463	657	953	435	400	588	981	2,422	2,403
Tax	91	125	148	242	107	98	141	216	605	561
ETR (%)	25.9	27.0	22.4	25.4	24.5	24.4	24.0	22.0	25.0	23.3
Reported PAT	258	338	510	711	328	303	447	765	1,817	1,842
Adj. PAT	258	338	510	711	328	303	447	765	1,817	1,842
YoY Change (%)	81.1	60.2	53.0	28.4	26.9	(10.4)	(12.4)	7.6	46.5	1.4
Adj. EPS	4.6	6.0	9.1	12.7	5.9	5.4	8.0	13.7	32.4	32.9

Exhibit 2: Quarterly order book

(Rs mn)	1QFY24	2QFY24	3QFY24	4QFY24	FY24	1QFY25	2QFY25	3QFY25	4QFY25E	FY25E
Production	3,191	5,919	3,177	4,874	4,874	4,374	3,886	5,145	5,567	5,567
YoY Growth (%)	15.4	108.1	(5.8)	70.1	70.1	37.0	(34.4)	61.9	14.2	14.2
Development	5,996	3,712	6,066	5,524	5,524	5,391	5,343	5,145	6,415	6,415
YoY Growth (%)	408.6	(24.8)	22.0	(6.6)	(6.6)	(10.1)	43.9	(15.2)	16.1	16.1
Service	484	401	385	433	433	407	486	657	484	484
YoY Growth (%)	(18.0)	(31.5)	(27.7)	(6.2)	(6.2)	(15.9)	21.0	70.5	11.7	11.7
Closing Order Book	9,671	10,032	9,628	10,831	10,831	10,171	9,714	10,947	12,103	12,103
YoY Growth (%)	113.3	19.9	8.4	17.2	17.2	5.2	(3.2)	13.7	11.7	11.7
Order Inflow	1,327	1,444	991	3,026	6,788	381	453	2,403	3,763	7,000
YoY Growth (%)	189.7	(69.4)	(39.3)	36.8	(24.7)	(71.3)	(68.6)	142.5	24.3	3.1
Revenue	897	1,083	1,395	1,823	5,198	1,041	910	1,170	2,607	5,728
YoY Growth (%)	31.1	22.8	24.8	(1.5)	14.6	16.0	(16.0)	(16.1)	43.0	10.2

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 3: Annual closing order book position



Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 4: EBITDA movement






Exhibit 5: Detailed financials

Y/E March (Rsmm)	3QFY24	2QFY25	3QFY25	YoY (%)	QoQ (%)	Estimates	Variance (%)	FY24	FY25E	YoY (%)
Net Sales	1,395	910	1,170	(16.1)	28.6	1,604	(27.0)	5,198	5,728	10.2
Expenditure										
Raw Material Consumed	415	496	785	89.1	58.3	-	-	1,808	2,710	49.9
Changes in Inventory	36	(277)	(555)	(1,657.6)	NA	-	-	(157)	(904)	NA
Employee Costs	262	266	292	11.3	9.7	-	-	990	1,230	24.2
Other Expenses	82	82	108	31.8	30.8	-	-	341	456	33.8
Total Expenditure	795	567	630	(20.7)	11.1	1,051	(40.0)	2,982	3,492	17.1
EBITDA	600	343	540	(10.0)	57.5	553	(2.4)	2,216	2,237	0.9
EBITDA Margin (%)	43.0	37.7	46.2	313bps	848bps	34.5	1167bps	42.6	39.0	(359)bps
Depreciation	33	35	35	5.2	(0.3)	-	-	161	189	17.4
Interest	23	28	32	37.1	12.4	-	-	93	121	30.1
Other income	113	120	114	0.6	(5.6)	-	-	460	477	3.7
Exceptional Items	-	-	-	-	-	-	-	-	-	
PBT	657	400	588	(10.6)	46.8	-	-	2,422	2,403	(0.8)
Tax	148	98	141	(4.5)	44.5	-	-	605	561	(7.3)
Reported PAT	510	303	447	(12.4)	47.5	-	-	1,817	1,842	1.4
Adjusted PAT	510	303	447	(12.4)	47.5	455	(1.8)	1,817	1,842	1.4
NPM (%)	36.5	33.3	38.2	162bps	489bps	28.3	981bps	35.0	32.2	(279)bps
EPS (Rs.)	9.1	5.4	8.0	(12.4)	47.5	8.1	(1.8)	32.4	32.9	1.4

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 6: Change in estimates

Particulars	New			Old			% Change		
(Rs mn)	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Net Sales	5,728	7,099	8,623	6,080	7,429	9,018	(5.8)	(4.4)	(4.4)
EBITDA	2,237	2,764	3,237	2,294	2,804	3,375	(2.5)	(1.4)	(4.1)
Adj. PAT	1,842	2,246	2,543	1,910	2,281	2,656	(3.6)	(1.5)	(4.3)
Adj. EPS	33	40	45	34	41	47	(3.6)	(1.5)	(4.3)

Source: Nirmal Bang Institutional Equities Research

Exhibit 7: Actual performance v/s NBIE & Consensus estimates

Particulars					
2QFY25 (Rs mn)	Actual	Our Estimate	Deviation (%)	Bloomberg Consensus	Deviation (%)
Revenue	1,170	1,604	(27.0)	1,925	(39.2)
EBITDA	540	553	(2.4)	815	(33.7)
PAT	447	455	(1.8)	661	(32.4)



3QFY25 earnings call highlights

Revenue and Order Book Performance:

- The management maintains its order book of Rs11.8bn, which includes negotiated orders of Rs890mn. The order inflow of Rs2.4bn in 3QFY25 has seen a 2.5x growth as compared to 3QFY24. This brings the order inflow of 9MFY25 to Rs3.2bn. This growth has been driven by both development and production contracts.
- A substantial amount of revenue and order inflow was driven by the export market. The company is working on expanding its presence in the export markets.
- International order books currently stand at Rs1bn, which is 9% of the total order book and it expects another Rs20-30bn in the coming months.
- In Q3, the company secured a production order for Electronic Warfare Systems worth Rs.800mn, a Radar production order worth Rs.530mn, and an Avionics export order worth Rs.530mn.
- Production/Development/Service contributed 59%/37%/4% of the revenue, respectively. Of which, Radar and Automated Test Equipment contributed to 62% and 18% of the revenue, respectively.
- A 16% decrease in execution was mainly due to delays in deliveries on client request. The management is expecting some clarity in the coming weeks.
- Inventory days were higher due to two large contracts for Radars undertaken by the company. One of these contracts will be delivered by March 2025 and the other will be delivered by Q1/Q2FY26

Geographic Expansion and Sectoral Growth:

- Drawing on its core strengths, the company has expanded into key global markets like Europe and East Asia, effectively competing with major OEMs. Going forward, it aims to grow its addressable market by focusing on complete systems.
- The company is looking to set up a proper marketing organization to increase focus on exports.
- The company's export operations include supplying subsystems and development deliveries for foreign OEMs, which plan business years in advance. This enables a stable revenue stream on a quarterly and monthly basis, blending capex tender business with growing recurring revenue.

Order Pipeline and Growth Prospects:

- The management has hinted that overall, the company has participated in major programs, with its products being accepted, and the related bids are expected to take place soon.
- The company is actively participating in several upcoming defence contracts, including army contracts, though projections are uncertain until tenders open and L1 status is determined. While some planned contracts for this year and next have been delayed due to external factors, they remain live, with tenders expected to be released within the next 5-8 months.
- Major programs have faced delays due to government clearances and funding, but DRDO has sanctioned several new programs where the company is well-positioned, especially in EW and complete system capabilities. Approved products are awaiting user acceptance. The company is working closely with DRDO and has engaged with the Ministry of Defence to encourage domestic procurement over imports.


QIP Allocation:


 The company raised Rs5bn through QIP, of which it has spent Rs0.8bn on radars, UW suite, software development radios.



Exhibit 8: Revenue decreased by 16% YoY








Source: Company, Nirmal Bang Institutional Equities Research

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 10: EBITDA margin at 46%

Exhibit 11: Employee cost at 25% of sales







Source: Company, Nirmal Bang Institutional Equities Research

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 12: PAT margin at 38%

Exhibit 13: EPS down by 12% YoY





Source: Company, Nirmal Bang Institutional Equities Research




Exhibit 14: Valuation summary

Particulars	(Rs mn)
Dec'26 EPS	39.1
Target multiple (x)	62.0
Value per share (Rs)	2,423
CMP (Rs)	2,027
Upside / (downside) %	19.5%

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 15: Rolling valuation charts



Source: Company, Nirmal Bang Institutional Equities Research



Financial Statements

Exhibit 16: Income statement

Y/E March (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Net Sales	4,534	5,198	5,728	7,099	8,623
Growth YoY%	45.9	14.6	10.2	23.9	21.5
Gross profit	2,825	3,547	3,922	4,777	5,893
Gross margin %	62.3	68.2	68.5	67.3	68.3
Staff costs	794	990	1,230	1,456	1,885
% of sales	17.5	19.0	21.5	20.5	21.9
Other expenses	312	341	456	556	772
% of sales	6.9	6.6	8.0	7.8	9.0
EBITDA	1,719	2,216	2,237	2,764	3,237
Growth YoY%	22.0	28.9	0.9	23.6	17.1
EBITDA margin %	37.9	42.6	39.0	38.9	37.5
Depreciation	85	161	189	264	339
EBIT	1,634	2,055	2,047	2,500	2,897
Interest	77	93	121	60	60
Other income	92	460	477	440	424
PBT (bei)	1,649	2,422	2,403	2,880	3,261
PBT	1,649	2,422	2,403	2,880	3,261
ETR	25%	25%	23%	22%	22%
PAT	1,240	1,817	1,842	2,246	2,543
Adj PAT	1,240	1,817	1,842	2,246	2,543
Growth YoY%	32.0	46.5	1.4	21.9	13.2

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 18: Balance sheet

Y/E March (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Share capital	112	112	112	112	112
Reserves	11,558	13,130	14,598	16,388	18,414
Net worth	11,670	13,242	14,710	16,500	18,526
Long term debt	7	29	29	29	29
Short term debt	18	7	7	7	7
Total debt	25	35	35	35	35
Net debt	(5,453)	(3,892)	(5,006)	(6,618)	(7,094)
Other non-current liabilities	1,307	21	21	21	21
Total Equity & Liabilities	14,349	16,918	19,454	22,008	24,512
Gross block	1,090	1,519	2,269	3,019	3,769
Accumulated depreciation	177	313	502	767	1,106
Net Block	912	1,206	1,766	2,252	2,663
CWIP	14	72	72	72	72
Intangible and others	20	427	427	427	427
Other non-current assets	901	926	926	926	926
Investments	188	278	278	278	278
Trade receivables	3,825	3,988	2,982	3,112	3,733
Inventories	1,930	2,668	4,535	4,862	5,859
Cash & Cash Equivalents	5,478	3,927	5,041	6,653	7,129
Other current assets	1,083	3,426	3,426	3,426	3,426
Total current assets	12,315	14,009	15,984	18,053	20,146
Trade payables	431	501	1,569	2,334	2,811
Other current liabilities	815	2,995	2,995	2,995	2,995
Total current liabilities	1,263	3,502	4,570	5,335	5,812
Total Assets	14,349	16,918	19,454	22,008	24,512

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 17: Cash flow

Y/E March (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
PBT	1,649	2,422	2,403	2,880	3,261
Depreciation	85	161	189	264	339
Interest	-	93	121	60	60
Other adjustments	41	(439)	(477)	(440)	(424)
Change in Working capital	(2,580)	(992)	207	308	(1,140)
Tax paid	(534)	(631)	(561)	(634)	(717)
Operating cash flow	(172)	1,394	1,883	2,438	1,379
Capex	(385)	(460)	(750)	(750)	(750)
Free cash flow	(557)	934	1,133	1,688	629
Other investing activities	(3,443)	(1,779)	-	-	-
Investing cash flow	(3,828)	(2,239)	(750)	(750)	(750)
Issuance of share capital	-	-	-	-	-
Movement of Debt	-	(77)	-	-	-
Dividend paid (incl DDT)	4,380	(252)	(374)	(457)	(517)
Other financing activities	-	(97)	356	380	364
Financing cash flow	4,380	(425)	(19)	(77)	(153)
Net change in cash flow	381	(1,271)	1,114	1,612	476
Opening C&CE	1,771	2,152	881	5,041	6,653
Closing C&CE	2,152	881	5,041	6,653	7,129
Source: Company Nirmal Pana Institutional Equition Pageorch					

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 19: Key ratios


•						
Y/E March	FY23	FY24	FY25E	FY26E	FY27E	
Per share (Rs)						
Adj EPS	22.1	32.4	32.9	40.1	45.4	
Book value	208.4	236.5	262.7	294.6	330.8	
DPS	4.5	6.6	6.7	8.2	9.2	
Valuation (x)						
P/Sales	24.3	21.2	19.3	15.5	12.8	
EV/EBITDA	61.0	48.0	47.1	37.5	31.9	
P/E	89.0	60.7	59.9	49.1	43.4	
P/BV	9.5	8.3	7.5	6.7	6.0	
Return ratios (%)						
RoCE	14.0	12.3	11.2	12.5	12.9	
RoCE (pre-tax)	18.7	16.5	14.6	16.0	16.5	
RoE	14.2	14.6	13.2	14.4	14.5	
RoIC	23.9	19.8	16.5	19.9	21.2	
Profitability ratios (%)						
Gross margin	62.3	68.2	68.5	67.3	68.3	
EBITDA margin	37.9	42.6	39.0	38.9	37.5	
PAT margin	27.3	35.0	32.2	31.6	29.5	
Liquidity ratios (%)						
Current ratio	9.7	4.0	3.5	3.4	3.5	
Quick ratio	8.2	3.2	2.5	2.5	2.5	
Solvency ratio (%)						
Net Debt to Equity ratio	(0.5)	(0.3)	(0.3)	(0.4)	(0.4)	
Turnover ratios						
Fixed asset turnover ratio (x)	5.4	3.9	3.0	2.7	2.5	
Debtor days	234	200	190	160	158	
Inventory days	334	300	289	250	248	
Creditor days	87	95	100	120	119	
Net Working capital days	481	405	379	290	287	
Courses Company Nimes Bone Institutional Familias Bone						



Rating track

Date	Rating	Market price (Rs)	Target price (Rs)
5 April 2024	Hold	2,693	2,755
22 May 2024	Hold	3,176	3,226
18 July 2024	Hold	3,152	3,017
31 July 2024	Hold	3,284	3,124
11 October 2024	Buy	2,497	3,051
12 November 2024	Buy	2,186	2,881
10 January 2025	Buy	2,234	2,651
06 February 2025	Buy	2,027	2,423

Rating track graph





DISCLOSURES

This Report is published by Nirmal Bang Equities Private Limited (hereinafter referred to as "NBEPL") for private circulation. NBEPL is a registered Research Analyst under SEBI (Research Analyst) Regulations, 2014 having Registration no. INH000001436. NBEPL is also a registered Stock Broker with National Stock Exchange of India Limited and BSE Limited in cash and derivatives segments.

NBEPL has other business divisions with independent research teams separated by Chinese walls, and therefore may, at times, have different or contrary views on stocks and markets.

NBEPL or its associates have not been debarred / suspended by SEBI or any other regulatory authority for accessing / dealing in securities Market. NBEPL, its associates or analyst or his relatives do not hold any financial interest in the subject company. NBEPL or its associates or Analyst do not have any conflict or material conflict of interest at the time of publication of the research report with the subject company. NBEPL or its associates or Analyst or his relatives do not hold beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of this research report.

NBEPL or its associates / analyst has not received any compensation / managed or co-managed public offering of securities of the company covered by Analyst during the past twelve months. NBEPL or its associates have not received any compensation or other benefits from the company covered by Analyst or third party in connection with the research report. Analyst has not served as an officer, director or employee of Subject Company and NBEPL / analyst has not been engaged in market making activity of the subject company.

Analyst Certification: I, Jyoti Gupta, research analyst the author of this report, hereby certify that the views expressed in this research report accurately reflects my personal views about the subject securities, issuers, products, sectors or industries. It is also certified that no part of the compensation of the analyst was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The analyst is principally responsible for the preparation of this research report and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations.



Disclaimer

Stock Ratings Absolute Returns

BUY > 15%

HOLD -5% to14%

SELL < -5%

This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. NBEPL is not soliciting any action based upon it. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any such transaction. In preparing this research, we did not take into account the investment objectives, financial situation and particular needs of the reader.

This research has been prepared for the general use of the clients of NBEPL and must not be copied, either in whole or in part, or distributed to any other person in any form. If you are not the intended recipient you must not use or disclose the information in this research in any way. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. NBEPL will not treat recipients as customers by virtue of their receiving this report. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NBEPL & its group companies to registration or licensing requirements within such jurisdictions.

The report is based on the information obtained from sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up-to-date and it should not be relied upon as such. We accept no obligation to correct or update the information or opinions in it. NBEPL or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. NBEPL or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

This information is subject to change without any prior notice. NBEPL reserves its absolute discretion and right to make or refrain from making modifications and alterations to this statement from time to time. Nevertheless, NBEPL is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries.

Before making an investment decision on the basis of this research, the reader needs to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of their particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. Opinions expressed are subject to change without any notice. Neither the company nor the director or the employees of NBEPL accept any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Here it may be noted that neither NBEPL, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profit that may arise from or in connection with the use of the information contained in this report.

Copyright of this document vests exclusively with NBEPL.

*"Registration granted by SEBI and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors." Our reports are also available on our website www.nirmalbang.com

Access all our reports on Bloomberg, Thomson Reuters and Factset.

Team Details:			
Name		Email Id	Direct Line
Rahul Arora	CEO	rahul.arora@nirmalbang.com	-
Krishnan Sambamoorthy	Head of Research	krishnan.s@nirmalbang.com	+91 22 6273 8210
Dealing			
Ravi Jagtiani	Dealing Desk	ravi.jagtiani@nirmalbang.com	+91 22 6273 8230, +91 22 6636 8833
Michael Pillai	Dealing Desk	michael.pillai@nirmalbang.com	+91 22 6273 8102/8103, +91 22 6636 8830

Nirmal Bang Equities Pvt. Ltd.

Correspondence Address

B-2, 301/302, Marathon Innova,

Nr. Peninsula Corporate Park,

Lower Parel (W), Mumbai-400013.

Board No.: 91 22 6273 8000/1; Fax.: 022 6273 8010